학술논문

Prions and Neurodegenerative Diseases: A Focus on Alzheimer's Disease.
Document Type
article
Source
Journal of Alzheimer's Disease. 85(2)
Subject
Biomedical and Clinical Sciences
Biological Psychology
Clinical Sciences
Neurosciences
Psychology
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Brain Disorders
Aging
Neurodegenerative
Infectious Diseases
Dementia
Alzheimer's Disease
Transmissible Spongiform Encephalopathy (TSE)
Acquired Cognitive Impairment
Emerging Infectious Diseases
Rare Diseases
Aetiology
2.1 Biological and endogenous factors
Neurological
Alzheimer Disease
Amyloid beta-Peptides
Animals
Humans
Neurofibrillary Tangles
Neurons
Prion Proteins
Protein Aggregation
Pathological
Randomized Controlled Trials as Topic
Receptor
Metabotropic Glutamate 5
alpha-Synuclein
tau Proteins
Alzheimer's disease
A beta oligomers
amyloid-beta
amyloid-beta protein precursor
neurodegenerative diseases
prion protein
prion protein refolding
prions
tau pathologies A beta O-induced signal cascade
Alzheimer’s disease
Aβ oligomers
amyloid-β
amyloid-β protein precursor
tau pathologies AβO-induced signal cascade
Cognitive Sciences
Neurology & Neurosurgery
Clinical sciences
Biological psychology
Language
Abstract
Specific protein misfolding and aggregation are mechanisms underlying various neurodegenerative diseases such as prion disease and Alzheimer's disease (AD). The misfolded proteins are involved in prions, amyloid-β (Aβ), tau, and α-synuclein disorders; they share common structural, biological, and biochemical characteristics, as well as similar mechanisms of aggregation and self-propagation. Pathological features of AD include the appearance of plaques consisting of deposition of protein Aβ and neurofibrillary tangles formed by the hyperphosphorylated tau protein. Although it is not clear how protein aggregation leads to AD, we are learning that the cellular prion protein (PrPC) plays an important role in the pathogenesis of AD. Herein, we first examined the pathogenesis of prion and AD with a focus on the contribution of PrPC to the development of AD. We analyzed the mechanisms that lead to the formation of a high affinity bond between Aβ oligomers (AβOs) and PrPC. Also, we studied the role of PrPC as an AβO receptor that initiates an AβO-induced signal cascade involving mGluR5, Fyn, Pyk2, and eEF2K linking Aβ and tau pathologies, resulting in the death of neurons in the central nervous system. Finally, we have described how the PrPC-AβOs interaction can be used as a new potential therapeutic target for the treatment of PrPC-dependent AD.